Avatrombopag
Chemical compound
- US DailyMed: Avatrombopag
category
- AU: B3[1]
administration
- B02BX08 (WHO)
- 1-[3-Chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid
- 570406-98-3
N
- 9852519
- DB11995
Y
- 8028230 Y
- 3H8GSZ4SQL
- D10306
- as salt: D10307
- ChEMBL2103883 N
- DTXSID30205667
- Interactive image
- C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl
- InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38)Y
- Key:OFZJKCQENFPZBH-UHFFFAOYSA-N
N
Y (what is this?)Avatrombopag, sold under the brand name Doptelet, is a medication that used for certain conditions that lead to thrombocytopenia (low platelets) such as thrombocytopenia associated with chronic liver disease in adults who are to undergo a planned medical or dental procedure.[8][9] It was approved for medical use in the United States in May 2018,[10][11] the European Union in June 2019,[7] and Australia in January 2023.[1]
It acts as a thrombopoietin receptor agonist.[12]
References
- ^ a b c "Doptelet". Therapeutic Goods Administration (TGA). 30 January 2023. Archived from the original on 5 February 2023. Retrieved 8 April 2023.
- ^ "Doptelet (Swedish Orphan Biovitrum Pty Ltd)". Therapeutic Goods Administration (TGA). 16 February 2023. Archived from the original on 27 March 2023. Retrieved 8 April 2023.
- ^ "AusPAR: Doptelet". Therapeutic Goods Administration (TGA). 8 February 2024. Retrieved 31 March 2024.
- ^ "Details for: Doptelet". Health Canada. 22 January 2024. Archived from the original on 3 March 2024. Retrieved 3 March 2024.
- ^ "Summary Basis of Decision for Doptelet". Health Canada. 17 May 2024. Retrieved 8 June 2024.
- ^ "Doptelet- avatrombopag maleate tablet, film coated". DailyMed. 1 July 2021. Archived from the original on 3 March 2024. Retrieved 3 March 2024.
- ^ a b "Doptelet EPAR". European Medicines Agency (EMA). 24 April 2019. Archived from the original on 22 May 2020. Retrieved 2 May 2020.
- ^ Abdela J (2019). "Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag". Clinical Medicine Insights. Blood Disorders. 12: 1179545X19875105. doi:10.1177/1179545X19875105. PMC 6804364. PMID 31673229.
- ^ Markham A (November 2021). "Avatrombopag: A Review in Thrombocytopenia". Drugs. 81 (16): 1905–1913. doi:10.1007/s40265-021-01613-y. PMC 8610948. PMID 34709601.
- ^ "FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure". U.S. Food and Drug Administration (FDA) (Press release). 21 May 2018. Archived from the original on 11 December 2019. Retrieved 2 May 2020.
- ^ "Drug Approval Package: Doptelet (avatrombopag)". U.S. Food and Drug Administration (FDA). 28 June 2018. Archived from the original on 7 April 2021. Retrieved 2 May 2020.
- ^ Kuter DJ (November 2021). "The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag". Blood Reviews. 53: 100909. doi:10.1016/j.blre.2021.100909. PMID 34815110. S2CID 244285488.
- v
- t
- e
(coagulation)
| Systemic |
| ||||||
|---|---|---|---|---|---|---|---|
| Local |
Portal:
Medicine
 | This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
